Urinary Incontinence - Pipeline Review, H2 2016

Date: July 13, 2016
Pages: 81
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: U76CE9897D1EN
Leaflet:

Download PDF Leaflet

Urinary Incontinence - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Urinary Incontinence - Pipeline Review, H2 2016’, provides an overview of the Urinary Incontinence pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Urinary Incontinence
  • The report reviews pipeline therapeutics for Urinary Incontinence by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Urinary Incontinence therapeutics and enlists all their major and minor projects
  • The report assesses Urinary Incontinence therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Urinary Incontinence
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Urinary Incontinence Overview
Therapeutics Development
Pipeline Products for Urinary Incontinence - Overview
Pipeline Products for Urinary Incontinence - Comparative Analysis
Urinary Incontinence - Therapeutics under Development by Companies
Urinary Incontinence - Therapeutics under Investigation by Universities/Institutes
Urinary Incontinence - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Urinary Incontinence - Products under Development by Companies
Urinary Incontinence - Products under Investigation by Universities/Institutes
Urinary Incontinence - Companies Involved in Therapeutics Development
Astellas Pharma Inc.
Celogos
Cook MyoSite Incorporated
FemmePharma Global Healthcare, Inc.
GTx, Inc.
Innovacell Biotechnologie AG
Ipsen S.A.
Outpost Medicine Limited
Taiho Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited
TheraVida, Inc.
Urinary Incontinence - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(mirabegron + solifenacin succinate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
abobotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-2205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enobosarm - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gtx-027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICES-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OP-233 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prof-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RCD-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit NET for Stress Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAS-303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THVD-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THVD-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Urinary Incontinence - Dormant Projects
Urinary Incontinence - Discontinued Products
Urinary Incontinence - Product Development Milestones
Featured News & Press Releases
Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-024 (enobosarm) on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting
Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-027 on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting
Jan 13, 2016: GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence
Oct 13, 2015: GTx Receives FDA Clearance to Initiate Clinical Trial in Stress Urinary Incontinence
May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial
Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg
Jan 03, 2013: TheraVida Announces Positive Top-line Phase II Results For Tolenix In Patients With Overactive Bladder And Urge Urinary Incontinence
Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference
Dec 05, 2011: Pfizer’s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients
Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency
Aug 30, 2011: Innovacell passes a further milestone
May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence
Mar 22, 2011: TheraVida Announces Positive Results From Phase I Trial Of THVD-201
Feb 22, 2011: Innovacell makes further progress on product development
Jun 28, 2010: Astellas and Teva reached a Settlement Agreement on VESIcare Patent Case
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Urinary Incontinence, H2 2016
Number of Products under Development for Urinary Incontinence - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Urinary Incontinence - Pipeline by Astellas Pharma Inc., H2 2016
Urinary Incontinence - Pipeline by Celogos, H2 2016
Urinary Incontinence - Pipeline by Cook MyoSite Incorporated, H2 2016
Urinary Incontinence - Pipeline by FemmePharma Global Healthcare, Inc., H2 2016
Urinary Incontinence - Pipeline by GTx, Inc., H2 2016
Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H2 2016
Urinary Incontinence - Pipeline by Ipsen S.A., H2 2016
Urinary Incontinence - Pipeline by Outpost Medicine Limited, H2 2016
Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
Urinary Incontinence - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Urinary Incontinence - Pipeline by TheraVida, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Urinary Incontinence - Dormant Projects, H2 2016
Urinary Incontinence - Dormant Projects (Contd..1), H2 2016
Urinary Incontinence - Dormant Projects (Contd..2), H2 2016
Urinary Incontinence - Discontinued Products, H2 2016
Urinary Incontinence - Discontinued Products (Contd..1), H2 2016

LIST OF FIGURES

Number of Products under Development for Urinary Incontinence, H2 2016
Number of Products under Development for Urinary Incontinence - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Fecal Incontinence - Pipeline Review, H2 2015 US$ 1,600.00 Jul, 2015 · 43 pages
Fecal Incontinence - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 43 pages
Urinary Incontinence - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Incontinence Devices - Pipeline Review, 2015 US$ 3,200.00 Oct, 2015 · 232 pages

Ask Your Question

Urinary Incontinence - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: